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Abstract
 
Little is known about innate immunity to bacteria after birth in the hitherto sterile fetal intes-
tine. Breast-feeding has long been associated with a lower incidence of gastrointestinal infec-
tions and inflammatory and allergic diseases. We found in human breast milk a 48-kD polypep-
tide, which we confirmed by mass spectrometry and sequencing to be a soluble form of the
bacterial pattern recognition receptor CD14 (sCD14). Milk sCD14 (m-sCD14) concentrations
were up to 20-fold higher than serum sCD14 from nonpregnant, pregnant, or lactating
women. In contrast, lipopolysaccharide (LPS)-binding protein was at very low levels. Mam-
mary epithelial cells produced 48-kD sCD14. m-sCD14 mediated activation by LPS and whole
bacteria of CD14 negative cells, including intestinal epithelial cells, resulting in release of innate
immune response molecules. m-sCD14 was undetectable in the infant formulas and commer-
cial (cows’) milk tested, although it was present in bovine colostrum. These findings indicate a
sentinel role for sCD14 in human milk during bacterial colonization of the gut, and suggest
that m-sCD14 may be involved in modulating local innate and adaptive immune responses,
thus controlling homeostasis in the neonatal intestine.
Key words: innate immunity • neonatal immunity • mucosal immunity • intestinal immune 
response • breast-feeding
 
Introduction
 
After birth, the sterile fetal intestine is heavily colonized
mainly by 
 
Escherichia coli
 
 and 
 
Streptococci
 
 (1). The predomi-
nance of endotoxin (LPS)-producing Gram-negative bac-
teria may contribute to the pathogenesis of a variety of
immune and inflammatory neonatal conditions, such as
necrotizing enterocolitis and gut-originated sepsis (2).
However, the epithelial layer, together with intraepithelial
and lamina propria immunocompetent cells, coordinates
local innate and adaptive immune responses, thus maintain-
ing gut homeostasis (3).
Importantly, it has been demonstrated that breast-fed
newborns experience a lower incidence of gastrointestinal
infections and inflammatory, respiratory, and allergic dis-
eases (4–6). Protection by milk has been variously ascribed
to maternal immunocompetent cells, immunoglobulins,
immune reactive peptides, antiinfectious oligosaccharides,
growth factors, cytokines, lysozyme, lactoferrin, and com-
plement components (7). However, we speculated that
more specific factors may be present in milk that would
continuously sense and signal to the neonate the presence
of microorganisms, thus contributing to maintain intestinal
immune homeostasis.
The bacterial pattern recognition receptor (PRR) CD14
plays a pivotal role in the recognition of and cell activation
induced by microbial cell wall components of Gram-nega-
tive and Gram-positive bacteria as well as mycobacteria (8,
9). Two soluble forms of CD14, sCD14
 
a
 
 and sCD14
 
b
 
, are
found in normal human plasma at a concentration of 2–3
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m
 
g/ml (10, 11). sCD14 binds to whole bacteria and bacte-
rial cell wall components, and mediates bacterial-induced
activation of cells that do not express membrane-bound
CD14 as well as CD14-bearing cells (12–14).
In view of this PRR activity of CD14, we tested
whether sCD14 is present in human milk and contributes
to the innate immune mechanisms controlling gut homeo-
stasis in newborns.
 
Materials and Methods
 
Reagents. 
 
Abs: anti-human CD14 mAb MY4 (IgG2b; Beck-
man Coulter) and MEM-18 (IgG1
 
k
 
; provided by Dr. V. Horejsi,
Academy of Sciences, Czech Republic) and their isotype-
matched controls MOPC 141 and MOPC 21, respectively
(Sigma-Aldrich). The rabbit anti-CD14 Ab (Sanofi) used in
Western blot analyses was raised in animals immunized with hu-
man recombinant sCD14 and cross-reacts with bovine and por-
cine CD14. LPS and nonpathogenic 
 
E. coli
 
 serotype O55:B5
were from Sigma-Aldrich.
 
Human Milk and Serum, Infant Milk Formulas, and Bovine
Milk.
 
Human serum and breast milk samples were collected
from healthy donors after written consent. Milk was processed
within 2 h of collection. After centrifugation, the cellular pellet
was used for analysis of macrophage-derived sCD14, and the
milk samples were kept at 
 
2
 
80
 
8
 
C until testing for sCD14 and
LPS-binding protein (LBP). Commercial infant milk formulas
were tested for sCD14 content and bioactivity after reconstitu-
tion. Commercial bovine milk (bottled, pasteurized cows’ milk)
was kept at 4
 
8
 
C before testing for sCD14. Bovine colostrum was
obtained from animals kept in local barns. sCD14 (Immuno-Bio-
logical Laboratories) and LBP (Hycult Biotechnology) concentra-
tions were determined by ELISA.
 
Western Blot Analysis.
 
Samples were separated by 12.5%
SDS-PAGE under reducing conditions (PhastSystem
 
®
 
; Amer-
sham Pharmacia Biotech, or Mini Protean II; Bio-Rad) and ana-
lyzed by Western blotting as described (11).
 
Isolation and Purification of m-sCD14, Mass Spectrometry, and Se-
quencing.
 
m-sCD14 was isolated from a pool of 3-mo-postpar-
tum breast milk samples by affinity chromatography in a
Sepharose 4B precolumn (Amersham Pharmacia Biotech) in tan-
dem to a CN-Br Sepharose 4B–coupled MEM-18 mAb (20 mg)
affinity column. The bound protein was eluted (PBS/50 mM di-
ethylamine, pH 11.5), dialyzed against PBS, and concentrated.
Some preparations were further purified by gel filtration on a Su-
perose 12 column (fast protein liquid chromatography [FPLC];
Amersham Pharmacia Biotech). The purity of the isolated protein
was confirmed by SDS-PAGE followed by silver staining, which
showed a single 48-kD polypeptide. For mass spectrometric anal-
yses, purified m-sCD14 was reduced, alkylated, and digested with
porcine trypsin and lysyl endopeptidase C (Lys-C) according to
standard protocols (15). Mass spectrometry (MS) and tandem MS
(MS/MS) of peptides were recorded in a nanoelectrospray Q-TOF
mass spectrometer (Micromass). Liquid chromatography/MS was
performed with an UltiMate NanoHPLC pump equipped with a
NanoColumn PepMap reverse phase (RP)HPLC (LC Packings)
on line with the nanoelectrospray source. NH
 
2
 
-terminal sequenc-
ing was performed in an Applied Biosystems sequencer according
to the Edman degradation protocol.
 
Cell Lines, Cell Activation, and Cytokine and Chemokine Determi-
nations.
 
The human colon carcinoma epithelial cell lines HT29
and SW620, myeloid cell line U937 (American Type Culture
Figure 1. Detection and characterization of sCD14 in human milk. (A)
Milk samples (1:25 to 1:200 dilutions) taken after the first week postpar-
tum and normal human serum (NHS) were tested for sCD14 by Western
blotting. Shown is the result of one sample representative of 10 donors.
(B) Analysis of m-sCD14 in milk samples taken at day 2 or day 10 post-
partum from the same mother. Samples from two donors are shown.
NHS, normal human serum. (C) m-sCD14 levels determined by ELISA
in multiple samples taken from 10 donors at different times postpartum.
Values correspond to the mean of triplicate determinations (SD # 6%).
The m-sCD14 molecular pattern of each sample was determined by
Western blotting and is indicated by the symbols. (D) NH2-terminal se-
quence (dashed line) and mass spectrometric analysis followed by amino
acid sequencing (solid line) of 48-kD m-sCD14 tryptic peptides showing
homology with the predicted sequence from monocyte CD14 cDNA.
Thick solid line underlines a peptide analyzed only by mass spectrometry.
X, not determined.
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clined over the time to values of 41.12 
 
6 
 
11.91 
 
m
 
g/ml (
 
n
 
 5
 
12; 
 
$
 
7 d postpartum). The serum sCD14 concentrations in
mothers after three and eight mo of pregnancy and after
three and six mo postpartum during lactation (Table I) re-
mained similar to those reported for normal donors (preg-
nancy, 3.71 
 
6 
 
0.57 
 
m
 
g/ml;
 
 n 
 
5 
 
20, and postpartum, 3.76 
 
6
 
0.56 
 
m
 
g/ml;
 
 n 
 
5 
 
20). However, the milk samples from the
same mothers showed significantly higher levels of m-sCD14
compared with serum sCD14 (14.84 
 
6 
 
6.40 
 
m
 
g/ml vs.
3.76 
 
6 
 
0.56 
 
m
 
g/ml;
 
 n 
 
5 
 
20; 
 
P 
 
, 
 
0.001; milk vs. serum,
three and six months postpartum). Thus, the high levels of
m-sCD14 did not reflect a systemic increase in sCD14 dur-
ing pregnancy and postpartum.
LBP, the protein that accelerates the binding of LPS to
sCD14 (16), was at a 1000-fold lower concentration in
milk than in serum of the same donor (Table I), in marked
contrast with the high levels of m-sCD14. Together, these
results indicated that sCD14 but not LBP is specifically ex-
pressed at high concentration in human milk.
 
Biochemical Characterization of m-sCD14.
 
The NH
 
2
 
-ter-
minal sequence of the 48-kD milk polypeptide (Fig 1 D),
present during most of the lactating period, was identical to
that reported for sCD14 from urine of nephrotic patients
and monocyte-derived CD14 (10, 17). No signal was de-
tected at position 18, which was consistent with an 
 
N
 
-gly-
cosylation at asparagine, as predicted by the CD14 cDNA
(17). Analysis of tryptic peptides from the purified material
by Q-TOF mass spectrometry and sequencing indicated
high homology with the amino acid sequence predicted by
the CD14 cDNA
 
 
 
(Fig 1 D). These results confirmed the
identity of m-sCD14 and indicated that differences in gly-
cosylation may account for the difference in electrophoretic
mobility and pattern between 48-kD m-sCD14 and serum
sCD14. Furthermore, m-sCD14 did not incorporate into
lipid micelles or elute with the void volume when sub-
jected to size exclusion chromatography (not shown), indi-
cating that it lacks the glycolipid tail (18).
 
Cellular Origin of m-sCD14. 
 
The extremely high con-
centration of sCD14 in milk and the presence, during most
of the lactating period, of a single 48-kD sCD14 polypep-
 
Collection), astrocytoma line U373 MG, and breast adenocarci-
noma cell line with characteristics of differentiated mammary epi-
thelium, MCF-7 (European Collection of Animal Cell Cultures),
were cultured as indicated by the purveyor. To test for CD14 ex-
pression, MCF-7 cells were cultured in AIM-V (GIBCO BRL)
serum-free medium (5 
 
3
 
 10
 
5
 
 cells/ml) for 72 h before analysis of
cell lysates and filtered supernatants by Western blotting. For cell
activation, 90% confluent cultures of HT29 (in 24-well plates),
SW620, and U373 (in 96-well plates) cells and the U937 cell line
(5 
 
3
 
 10
 
5
 
 cells/ml) were washed and cultured for an additional 24 h
in medium supplemented with normal human serum, FCS, or
milk in the absence or presence of 
 
E
 
.
 
 coli
 
 or 
 
E
 
.
 
 coli
 
 LPS before cul-
ture supernatants were tested for TNF-
 
a
 
 (Diaclone), epithelial
neutrophil activator (ENA)-78 (R&D Systems), IL-6, or IL-8 by
ELISA (IL-6– and IL-8–specific matched-pair Abs were from Im-
munokontact).
 
Results
 
Detection of sCD14 in Human Milk.
 
Western blot anal-
ysis using anti-CD14–specific Abs of breast milk samples
(
 
n
 
 5 
 
10) taken after the first week postpartum showed a
strong single 48-kD polypeptide band (Fig. 1 A). The par-
allel serum samples had the typical doublet of sCD14
 
b
 
 (56-
kD) and sCD14
 
a
 
 (50-kD) polypeptides, as described (11).
The sCD14 pattern in milk from the same subject at early
(
 
,
 
6 d), and late (
 
.
 
8 d) times postpartum was different
(Fig. 1 B). Most of the early samples had a complex sCD14
pattern with three polypeptide bands: a strong 48-kD
sCD14 polypeptide and two slower migrating polypeptides
of 
 
z
 
50 and 56 kD, which resembled serum sCD14
 
a
 
 and
 
b
 
, respectively. The later samples from the same subject
had a single 48-kD sCD14 band.
Levels of m-sCD14 in multiple milk samples from 10
donors, taken at different times postpartum (Fig. 1 C), were
very high (52.9 
 
6 
 
24.0 
 
m
 
g/ml;
 
 n 
 
5 
 
22) compared with
those reported for normal serum (2-3 
 
m
 
g/ml; reference 10).
The highest m-sCD14 levels were detected in the relatively
early samples (
 
#
 
6 d, 67.09 
 
6 
 
27.61 
 
m
 
g/ml;
 
 n 
 
5 
 
10). The
majority of these early samples showed the three-sCD14
polypeptide pattern (Fig. 1 B). m-sCD14 concentration de-
 
Table I.
 
Levels of sCD14 and LBP in Human Serum and Milk during Pregnancy and Postpartum
 
sCD14 LBP
Serum Milk Serum Milk
 
m
 
g/ml
 
m
 
g/ml
 
Pregnancy 3 mo 3.50 
 
6
 
 0.48 – 13.52 
 
6 
 
4.58 –
8 mo 3.92 
 
6 
 
0.61 – 17.21 
 
6
 
 3.01 –
Postpartum 5 d – 20.10 
 
6 
 
8.74 – 0.03 
 
6 
 
0.01
1 mo – 12.06 
 
6
 
 4.77 – 0.01 
 
6
 
 0.02
3 mo 3.71 
 
6 
 
0.59 12.16 
 
6 
 
3.75 10.65 
 
6 
 
2.39 0.01 
 
6 
 
0.01
6 mo 3.82 
 
6 
 
0.47 15.05 
 
6 
 
4.08 8.68 
 
6
 
 1.27 0.01 
 
6 0.01
Data represent mean 6 SD of 10 (sCD14) and 8 (LBP) samples tested by ELISA.
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tide contrasted with the level and pattern of monocyte-
derived sCD14 present in serum (reference 11; Table I and
Fig. 1). We therefore asked whether mammary gland cells
produced m-sCD14. Flow cytometric analysis of the mam-
mary epithelial cell line MCF-7 did not show surface ex-
pression of CD14 (not shown). However, cell lysates and
culture supernatants from serum-free cultured cells showed
CD14 polypeptide bands (Fig. 2 A). The culture superna-
tant showed a 48-kD sCD14 polypeptide similar to that
detected in relatively late milk samples. The cell lysate
showed two closely migrating CD14 polypeptides of z48
kD, one of them of slightly faster mobility, most likely rep-
resenting a precursor of the mature sCD14 glycoprotein.
Supernatants of serum-free cultured milk–derived mac-
rophages showed low levels of the typical serum sCD14a
and sCD14b isoforms (not shown).
m-sCD14 Is Absent from Infant Milk Formulas and Commer-
cial (Cows’) Milk. We asked whether presence of m-sCD14
is limited to breast milk. sCD14 was not detected in the
infant milk formulations (powdered milk) and commercial
cows’ milk (bottled, pasteurized milk) tested. However, it
was detectable in bovine colostrum and plasma (Fig. 2 B).
Endotoxin and Whole Bacteria Induce Cell Activation by a
Human Milk–mediated m-sCD14–dependent Mechanism.
Next, we asked whether m-sCD14 could function as a me-
diator of endotoxin activation of cells that lack cell mem-
brane CD14, as demonstrated for serum sCD14 (13). Hu-
man milk mediated LPS-induced IL-6 production by the
CD14-negative cell line U373 in a dose-dependent man-
ner (Fig. 3 A). Two anti-CD14 mAbs (MY4, MEM-18)
abrogated the IL-6 production, suggesting that m-sCD14
was critically involved in this activity. Importantly, bovine
colostrum and plasma, but not the powdered milk tested,
mediated IL-6 production by LPS-stimulated U373 cells
(not shown). Human milk also mediated LPS-induced IL-8
production by the CD14-negative myeloid cell line U937,
and this effect was blocked by MY4 (Fig. 3 B). We con-
firmed that m-sCD14 was responsible for the milk-medi-
ated cell activation by LPS, as purified m-sCD14 was able
to reproduce the effect of milk (Fig. 3 C).
We also tested the capacity of intestinal epithelial cell
(IEC) lines (HT-29 and SW620 lines) to produce immune
and proinflammatory molecules when challenged by en-
dotoxin or whole bacteria in the presence of human milk.
Figure 2. 48-kD sCD14 production by mammary epithelial cells and
absence from commercial infant milk formulas and cows’ milk. (A) De-
tection of sCD14 polypeptides by Western blotting in culture superna-
tants (Sup.) and total lysates (TL) from serum-free medium–cultured
mammary epithelial cell line MCF-7. Parallel analysis of m-sCD14 in
milk and normal human serum (NHS) is shown. Mr, relative molecular
mass. (B) Infant milk formulas (IF, 1:6 and 1:25 dilutions), cows’ milk
(bottled milk [BM]), bovine colostrum (BC), and bovine plasma (BP)
were tested for sCD14 by Western blotting. Shown is a representative re-
sult of 5 IF, 8 BM, 2 BC, and 10 BP.
Figure 3. m-sCD14 mediates LPS activation of CD14-negative cells.
(A and B) IL-6 and IL-8 production by the astrocytoma cell line U373
(A) and the myeloid cell line U937 (B), respectively, stimulated with E.
coli LPS (100 ng/ml) in medium supplemented with FCS, human AB se-
rum (AB), or human milk (HM). The anti-CD14 mAb MY4 and MEM-
18 but not their isotype-matched controls (20 mg/ml) blocked the LPS-
induced cell activation. (C) IL-6 production by LPS stimulated U373
cells in the presence of different amounts of purified milk–derived
sCD14. All cytokines were tested by ELISA. Results in A and C are
means 6 SD of triplicate cultures of one experiment representative of
four; results in B are the mean 6 SD of three independent experiments.
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IL-8 production by LPS-activated IEC was mediated by
human milk, and this activity was inhibited by an anti-
CD14 mAb (Fig. 4 A). Similarly, human milk mediated IL-8
production by IECs challenged with E. coli, and this ef-
fect was blocked by an anti-CD14 mAb (Fig. 4 B). IECs
also responded to bacteria by producing TNF-a and the
CXC chemokine, ENA-78; these responses were inhibited
by anti-CD14 mAb (Fig. 4, C and D). The m-sCD14–
mediated IEC activation by bacteria appears to be selective, as
expression of other immune response molecules (i.e., IL-7,
IL-15, IL-18, MHC class I and class II, and CD80) was not
affected (data not shown).
Discussion
Here, we demonstrate that the soluble form of the recep-
tor critically involved in innate recognition of bacteria,
CD14, is present and at high concentration in human milk.
Furthermore, we show that m-sCD14 can mediate IEC cell
activation induced by endotoxin and whole bacteria, result-
ing in the production of potent immune response and
proinflammatory mediators. Importantly, we found that
differentiated mammary epithelial cells are able to produce
sCD14 whose molecular pattern is identical to that of
sCD14 present in human milk during most of the lactating
period. This, together with the lack of correlation between
the high concentration of m-sCD14 and the corresponding
serum sCD14 levels during pregnancy and lactation, point
at the mammary gland epithelium as the main source of
m-sCD14. It should be noted that milk-derived macrophages
showed expression of the typical serum sCD14a and b iso-
forms. These sCD14 polypeptides were similar to those
which, in addition to the strong 48-kD sCD14 polypeptide
band, are part of the complex sCD14 pattern detectable in
early milk samples (Fig. 1 B). Thus, it is possible that milk
macrophage–derived sCD14 contributes to the total pool
of m-sCD14 within the first week postpartum. Addition-
ally, serum sCD14 may reach the milk by the paracellular
pathway, which allows components of the interstitial space
to pass between the alveolar epithelial cells (7). This process
does not operate during full lactation, explaining the disap-
pearance of sCD14a and b isoforms from late milk samples.
At first sight, it was surprising to find very low levels of
LBP in milk, in view of the role that this serum protein
plays in facilitating the interaction of LPS with CD14.
However, the low concentration of LBP may be beneficial
by leading to a more controlled immune response against
bacteria, as it was demonstrated that sCD14 can mediate
CD14-negative cell activation by LPS in the absence of
LBP, albeit with slower kinetics (16).
We consider two possible roles for m-sCD14: (i) in pro-
tection of the mammary gland against bacterial infection
during lactation, and (ii) in protection of the neonatal gut.
We have so far focused on the latter role.
The data show that m-sCD14–mediated in vitro stimu-
lation of IECs by LPS and Gram-negative bacteria results in
the release of molecules involved in cellular recruitment
and innate defense at the site of infection. However, a
number of mediators of epithelial–T cell communication
were not affected. These findings indicate that the m-sCD14–
mediated gut response is selective and modulated. Indeed,
our findings pose the question of why, given the heavy
bacterial colonization of the newborn’s intestine, the pres-
ence at high concentration of m-sCD14 does not result in
an excessive and deleterious immune response? One possi-
bility is that m-sCD14 loses bioactivity during transit
through the newborn’s stomach and proximal intestine.
The high load of m-sCD14 in the mother’s milk may be
necessary to compensate for such losses. We speculate that
high concentrations of m-sCD14 are provided for the
newborn to cope with the vast microbial inoculum and sig-
nal its presence to the neonatal intestine, which in turn will
Figure 4. IECs can be acti-
vated by LPS or whole bacteria
by an m-sCD14–dependent
mechanism. (A–D) IL-8, TNF-a,
and ENA-78 production was
tested by ELISA in supernatants
of HT29 and SW620 cell lines
cultured in medium supple-
mented with human milk (HM)
and stimulated with E. coli LPS
or varying numbers of whole E.
coli (C and D; 2.5 3 106 E. coli).
The anti-CD14 mAb MY4
(IgG2b) but not its isotype-
matched control blocked LPS
and bacterial stimulation. Repre-
sentative results with HT29 cells
are shown.
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initiate innate and adaptive immune responses. Modulation
of these responses, thus avoiding excessive immune and in-
flammatory reactions, may be achieved by several contrib-
uting mechanisms in which m-sCD14 is involved, includ-
ing the slow kinetics of cell activation by bacteria as a
consequence of the very low levels of LBP, endotoxin tol-
erization (19) resulting from this regulated level of cell acti-
vation, the selective response of the IEC to bacterial chal-
lenge described here, and the production of the potent
immunosuppressant prostaglandin E2 by the LPS-stimu-
lated lamina propria mononuclear cells, as has been sug-
gested (20). In addition, m-sCD14 may participate in mod-
ulating the gut immune response by interacting directly
(without LPS) with local T and B cells, which will cause
modulation of T and B cell activation and function, as we
recently described (21, 22).
In conclusion, the findings reported here indicate a sen-
tinel role for m-sCD14 during the neonatal period, consis-
tent with its PRR function in innate immunity, and sug-
gest an immunomodulatory activity of m-sCD14. We
propose that sCD14 in breast milk is responsible, at least in
part, for the association of breast-feeding with a lower inci-
dence of gastrointestinal infections and other inflammatory
and allergic conditions, which depends on adequate stimu-
lation of the gut immune system during microbial exposure
early in life.
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